suvorest 10fc tablet
advanced chemical industries limited - suvorexant - tablet - 10 mg
insoma tablet
globe pharmaceuticals ltd. - suvorexant - tablet - 10 mg
somarant tablet
incepta pharmaceuticals ltd. - suvorexant - tablet - 10 mg
suvorex 10 tablet
navana pharmaceuticals ltd. - suvorexant - tablet - 10 mg
suvotol tablet
square formulations ltd. - suvorexant - tablet - 10 mg
suvotol tablet
square pharmaceuticals plc, pabna - suvorexant - tablet - 10 mg
belsomra tablets 10mg (ベルソムラ錠10mg)
msd k.k. - suvorexant - very pale green tablet, diameter: 6.4mm, thickness: 4.1mm
belsomra tablets 15mg (ベルソムラ錠15mg)
msd k.k. - suvorexant - oval, white tablet, long diameter: 10.3mm, short diameter: 5.6mm, thickness: 4.0mm
belsomra tablets 20mg (ベルソムラ錠20mg)
msd k.k. - suvorexant - round, white tablet, diameter: 7.9mm, thickness: 4.9mm
itracap itraconazole 100 mg capsule blister pack
arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.